Earnings Call · Q3 FY2021·2021-11-09

Q3 21EPS +26.89%·Rev n/aQ2 21EPS +13.04%·Rev n/aQ1 21EPS +5.09%·Rev n/aQ4 20EPS -4.76%·Rev n/a⚠ consensus missing

Jazz Pharmaceuticals plc JAZZ

Andrea Flynn — Head of Investor Relations

Bruce Cozadd — Chairman and CEO

Daniel Swisher — President, U.S. Commercial Operations

Robert Iannone — Chief Scientific Officer

Renee Gala — Chief Financial Officer

+3.3%1d on move date+4.1% vs SPY3d+5.7%5d+4.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more JAZZ calls or request research access.

More JAZZ calls Browse calls Request research access